U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Dolor RJ, Melloni C, Chatterjee R, et al. Treatment Strategies for Women With Coronary Artery Disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Aug. (Comparative Effectiveness Reviews, No. 66.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Treatment Strategies for Women With Coronary Artery Disease

Treatment Strategies for Women With Coronary Artery Disease [Internet].

Show details

Appendix EList of Excluded Studies

    All studies listed below were reviewed in their full-text version and excluded. Following each reference, in italics, is the reason for exclusion. Reasons for exclusion signify only the usefulness of the articles for this study and are not intended as criticisms of the articles.

  1. Aaberge L, Aakhus S, Nordstrand K, et al. Myocardial performance after transmyocardial revascularization with CO(2)laser. A dobutamine stress echocardiographic study. Eur J Echocardiogr. 2001;2(3):187–96. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11882452]
  2. Aaberge L, Nordstrand K, Dragsund M, et al. Transmyocardial revascularization with CO(2) laser in patients with refractory angina pectoris. J Am Coll Cardiol. 2000;35(5):1170–1177. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10758957]
  3. Aaberge L, Rootwelt K, Blomhoff S, et al. Continued symptomatic improvement three to five years after transmyocardial revascularization with CO(2) laser: a late clinical follow-up of the Norwegian Randomized trial with transmyocardial revascularization. J Am Coll Cardiol. 2002;39(10):1588–93. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12020484]
  4. Aaberge L, Rootwelt K, Smith HJ, et al. Effects of transmyocardial revascularization on myocardial perfusion and systolic function assessed by nuclear and magnetic resonance imaging methods. Scand Cardiovasc J. 2001;35(1):8–13. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11354578]
  5. Aasa M, Dellborg M, Herlitz J, et al. Risk reduction for cardiac events after primary coronary intervention compared with thrombolysis for acute ST-elevation myocardial infarction (five-year results of the Swedish early decision reperfusion strategy [SWEDES] trial). Am J Cardiol. 2010;106(12):1685–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21126610]
  6. Aasa M, Henriksson M, Dellborg M, et al. Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial. Am Heart J. 2010;160(2):322–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20691839]
  7. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation. 2001;104(5):533–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11479249]
  8. Acampa W, Petretta M, Spinelli L, et al. Survival benefit after revascularization is independent of left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium. Eur J Nucl Med Mol Imaging. 2005;32(4):430–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15821962]
  9. Adgey J, Fox K, Flather M. Gusto Iv Acs. Br J Cardiol. 2000;7(11):663. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.
  10. Agati L, Funaro S, Madonna M, et al. Does coronary angioplasty after timely thrombolysis improve microvascular perfusion and left ventricular function after acute myocardial infarction? Am Heart J. 2007;154(1):151–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17584568]
  11. Anonymous. Arterial Revascularization Therapies Study (ARTS). Indian Heart J. 2001;53(2):239. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 11428490]
  12. Anonymous. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med. 1997;336(23):1621–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9173270]
  13. Anonymous. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet. 1993;341(8845):573–80. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8094826]
  14. Anonymous. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. 2002;360(9338):965–70. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12383664]
  15. Anonymous. Does PCI added to drug therapy improve outcomes in stable CAD? J Fam Pract. 2007;56(7):529. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 17612033]
  16. Anonymous. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation. 1992;86(1):100–10. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 1535568]
  17. Anonymous. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. JAMA. 1997;277(9):715–21. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9042843]
  18. Anonymous. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96(6):1761–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9323059]
  19. Anonymous. Little benefit to revascularization over intensive medical treatment in diabetes mellitus with coronary artery disease. J Natl Med Assoc. 2009;101(9):975–976. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.
  20. Anonymous. One-year survival following early revascularization for cardiogenic shock (SCHOCK trial). Indian Heart J. 2001;53(2):240. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 11428491]
  21. Anonymous. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet. 2001;358(9286):951–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11583747]
  22. Aoki J, Ong AT, Arampatzis CA, et al. Comparison of three-year outcomes after coronary stenting versus coronary artery bypass grafting in patients with multivessel coronary disease, including involvement of the left anterior descending coronary artery proximally (a subanalysis of the arterial revascularization therapies study trial). Am J Cardiol. 2004;94(5):627–31. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15342295]
  23. Aoki J, Ong AT, Hoye A, et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. Eur Heart J. 2005;26(15):1488–93. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15860519]
  24. Armstrong PW. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J. 2006;27(13):1530–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16757491]
  25. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002;287(15):1943–51. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11960536]
  26. Baldus S, Köster R, Küchler R, et al. [Percutaneous revascularization of multivessel coronary disease using stents - a multicenter, prospective study]. Dtsch Med Wochenschr. 2002;(11):547–52. Exclude - Non-English. [PubMed: 11894174]
  27. Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010;55(11):1067–75. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20079596]
  28. Barnett PG, Chen S, Boden WE, et al. Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction: results of a randomized trial. Circulation. 2002;105(6):680–4. Exclude - Does not include outcomes of interest. [PubMed: 11839621]
  29. Bata I, Armstrong PW, Westerhout CM, et al. Time from first medical contact to reperfusion in ST elevation myocardial infarction: a Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy. Can J Cardiol. 2009;25(8):463–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2732387] [PubMed: 19668780]
  30. Bell MR, Grill DE, Garratt KN, et al. Long-term outcome of women compared with men after successful coronary angioplasty. Circulation. 1995;91(12):2876–81. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 7796495]
  31. Bell MR, Holmes DR Jr, Berger PB, et al. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. JAMA. 1993;269(16):2091–5. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 8468762]
  32. Ben-Gal Y, Moses JW, Mehran R, et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC Cardiovasc Interv. 2010;(10):1059–67. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20965465]
  33. Berger PB, Velianou JL, Aslanidou Vlachos H, et al. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol. 2001;38(5):1440–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11691521]
  34. Berrocal DH, Cohen MG, Spinetta AD, et al. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase. Am Heart J. 2003;146(6):E22. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14661011]
  35. Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998;338(25):1785–92. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9632444]
  36. Bohmer E, Arnesen H, Abdelnoor M, et al. The NORwegian study on DIstrict treatment of ST-elevation myocardial infarction (NORDISTEMI). Scand Cardiovasc J. 2007;41(1):32–8. Exclude - Does not include outcomes of interest. [PubMed: 17365975]
  37. Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55(2):102–10. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19747792]
  38. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002;360(9336):825–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12243916]
  39. Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J. 2009;30(13):1598–606. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19429632]
  40. Bonnefoy E, Steg PG, Chabaud S, et al. Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial. Eur Heart J. 2005;26(17):1712–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15840623]
  41. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617–25. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC3290901] [PubMed: 21463153]
  42. Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation. 2008;118(4):381–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18606919]
  43. Borden WB, Redberg RF, Mushlin AI, et al. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305(18):1882–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 21558519]
  44. Borges JC, Lopes N, Soares PR, et al. Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. J Cardiothorac Surg. 2010;5(91) Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2987924] [PubMed: 20977758]
  45. Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol. 2011;57(5):538–45. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21272743]
  46. Bourassa MG, Kip KE, Jacobs AK, et al. Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery? The Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol. 1999;33(6):1627–36. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10334434]
  47. Brener SJ, Galla JM, Bryant R 3rd, et al. Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients. Am J Cardiol. 2008;101(2):169–72. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18178401]
  48. Brener SJ, Lytle BW, Casserly IP, et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation. 2004;109(19):2290–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15117846]
  49. Brener SJ, Murphy SA, Gibson CM, et al. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. Am J Cardiol. 2002;90(6):631–3. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 12231091]
  50. Brooks MM, Chung SC, Helmy T, et al. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation. 2010;122(17):1690–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2964421] [PubMed: 20937978]
  51. Brooks MM, Jones RH, Bach RG, et al. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. Circulation. 2000;101(23):2682–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10851204]
  52. Buller CE, Rankin JM, Carere RG, et al. Percutaneous coronary intervention in the Occluded Artery Trial: procedural success, hazard, and outcomes over 5 years. Am Heart J. 2009;158(3):408–15. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC2820255] [PubMed: 19699864]
  53. Buszman P, Tendera M, Bochenek A, et al. A prospective evaluation of early and late results of percutaneous and surgical revascularisation in patients with ischaemic left ventricular dysfunction. Kardiol Pol. 2002;56(1):57–61. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD.
  54. Buszman P, Wiernek S, Szymanski R, et al. Percutaneous versus surgical revascularization for multivessel coronary artery disease: a single center 10 year follow-up of SOS trial patients. Catheter Cardiovasc Interv. 2009;74(3):420–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19360866]
  55. Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008;51(5):538–45. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18237682]
  56. Campbell HE, Tait S, Buxton MJ, et al. A UK trial-based cost--utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris. Eur J Cardiothorac Surg. 2001;20(2):312–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11463549]
  57. Campbell HE, Tait S, Sharples LD, et al. Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris. Eur J Health Econ. 2005;6(4):288–97. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16195897]
  58. Cantor WJ, Burnstein J, Choi R, et al. Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study. Can J Cardiol. 2006;22(13):1121–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC2569051] [PubMed: 17102829]
  59. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705–18. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19553646]
  60. Cantor WJ, Goodman SG, Cannon CP, et al. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. Am Heart J. 2005;149(2):275–83. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15846265]
  61. Carrie D, Elbaz M, Puel J, et al. Five-year outcome after coronary angioplasty versus bypass surgery in multivessel coronary artery disease: results from the French Monocentric Study. Circulation. 1997;96(9 Suppl):II-1–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9386066]
  62. Carver A, Rafelt S, Gershlick AH, et al. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol. 2009;54(2):118–26. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19573727]
  63. Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120(25):2529–40. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2830563] [PubMed: 19920001]
  64. Chaitman BR, Rosen AD, Williams DO, et al. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. Circulation. 1997;96(7):2162–70. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9337185]
  65. Chauhan MS, Ho KK, Baim DS, et al. Effect of gender on in-hospital and one-year outcomes after contemporary coronary artery stenting. Am J Cardiol. 2005;95(1):101–4. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 15619402]
  66. Chen B, Wang W, Zhao H, et al. [Comparison of the clinical efficacy of recombinant tissue-type plasminogen activator thrombolysis with primary coronary stenting in acute myocardial infarction]. Zhonghua Nei Ke Za Zhi. 2002;(1):21–3. Exclude - Non-English. [PubMed: 11940291]
  67. Chew DP, Huang Z, Pieper KS, et al. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. Am Heart J. 2008;155(2):239–44. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18215592]
  68. Chung SC, Hlatky MA, Faxon D, et al. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). J Am Coll Cardiol. 2011;58(8):810–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC3164969] [PubMed: 21835316]
  69. Cisowski M, Drzewiecka-Gerber A, Ulczok R, et al. Primary direct stenting versus endoscopic atraumatic coronary artery bypass surgery in patients with proximal stenosis of the left anterior descending coronary artery--a prospective, randomised study. Kardiol Pol. 2004;61(9):253–61. discussion 262–4. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15531937]
  70. Cisowski M, Drzewiecki J, Drzewiecka-Gerber A, et al. Primary stenting versus MIDCAB: preliminary report-comparision of two methods of revascularization in single left anterior descending coronary artery stenosis. Ann Thorac Surg. 2002;74(4):S1334–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12400812]
  71. Claude J, Schindler C, Kuster GM, et al. Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J. 2004;25(24):2195–203. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15589636]
  72. Cleland JG, Calvert M, Freemantle N, et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011;13(2):227–33. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21156659]
  73. Cohen DJ. CABG and PCI did not differ clinically for angina relief in severe CAD. Ann Intern Med. 2011;155(2):JC1–10. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21768576]
  74. Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med. 2011;364(11):1016–26. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21410370]
  75. Courtis J, Rodes-Cabau J, Larose E, et al. Comparison of medical treatment and coronary revascularization in patients with moderate coronary lesions and borderline fractional flow reserve measurements. Catheter Cardiovasc Interv. 2008;71(4):541–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18307236]
  76. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110(10):1226–30. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15337693]
  77. Daemen J, Kuck KH, Macaya C, et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J Am Coll Cardiol. 2008;52(24):1957–67. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19055986]
  78. Dagenais GR, Lu J, Faxon DP, et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation. 2011;123(14):1492–500. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21444887]
  79. Dakik HA, Kleiman NS, Farmer JA, et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. Circulation. 1998;98(19):2017–23. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9808599]
  80. Damgaard S, Lund JT, Lilleor NB, et al. Comparably improved health-related quality of life after total arterial revascularization versus conventional coronary surgery-Copenhagen arterial revascularization randomized patency and outcome trial. Eur J Cardiothorac Surg. 2010. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20846874]
  81. Damgaard S, Lund JT, Lilleør NB, et al. Comparable three months’ outcome of total arterial revascularization versus conventional coronary surgery: Copenhagen Arterial Revascularization Randomized Patency and Outcome trial. J Thorac Cardiovasc Surg. 2008;135(5):1069–75. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 18455586]
  82. Damgaard S, Wetterslev J, Lund JT, et al. One-year results of total arterial revascularization vs. conventional coronary surgery: CARRPO trial. Eur Heart J. 2009;30(8):1005–11. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19270315]
  83. Davis KB, Chaitman B, Ryan T, et al. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study. J Am Coll Cardiol. 1995;25(5):1000–9. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 7897108]
  84. de Boer MJ, Ottervanger JP, van ‘t Hof AW, et al. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol. 2002;39(11):1723–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12039482]
  85. de Feyter PJ, Serruys PW, Unger F, et al. Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina. Circulation. 2002;105(20):2367–72. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12021222]
  86. De Servi S, Cavallini C, Dellavalle A, et al. Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome. Am Heart J. 2004;147(5):830–6. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 15131538]
  87. D’Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2(9):1060–8. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19761983]
  88. Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106(4):498–503. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC3005196] [PubMed: 20691307]
  89. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). Circulation. 1999;99(5):633–40. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9950660]
  90. Devlin G, Reynolds HR, Mark DB, et al. Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT). Am Heart J. 2011;161(1):84–90. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC3004529] [PubMed: 21167338]
  91. Di Pasquale P, Cannizzaro S, Giambanco F, et al. Immediate versus delayed facilitated percutaneous coronary intervention: a pilot study. J Cardiovasc Pharmacol. 2005;46(1):83–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15965359]
  92. Di Pasquale P, Cannizzaro S, Parrinello G, et al. Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings. J Thromb Thrombolysis. 2006;21(2):147–57. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16622610]
  93. Diderholm E, Andren B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J. 2002;143(5):760–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12040335]
  94. Diderholm E, Andren B, Frostfeldt G, et al. Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease. Am J Med. 2003;115(8):606–12. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14656612]
  95. Diderholm E, Andren B, Frostfeldt G, et al. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J. 2002;23(1):41–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11741361]
  96. Diegeler A, Spyrantis N, Matin M, et al. The revival of surgical treatment for isolated proximal high grade LAD lesions by minimally invasive coronary artery bypass grafting. Eur J Cardiothorac Surg. 2000;17(5):501–4. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10814909]
  97. Diegeler A, Thiele H, Falk V, et al. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med. 2002;347(8):561–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12192015]
  98. Diegeler A, Thiele H, Mohr FW, et al. [Comparison of PTCA and stent with minimal invasive bypass surgery for high grade stenosis of the Ramus interventricularis anterior]. Internistische Praxis. 2004;(4):697–710. Exclude - Non-English.
  99. Dieker HJ, van Horssen EV, Hersbach FM, et al. Transport for abciximab facilitated primary angioplasty versus on-site thrombolysis with a liberal rescue policy: the randomised Holland Infarction Study (HIS). J Thromb Thrombolysis. 2006;22(1):39–45. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16786231]
  100. Diercks DB, Owen KP, Kontos MC, et al. Gender differences in time to presentation for myocardial infarction before and after a national women’s cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). Am Heart J. 2010;160(1):80–87. e3. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20598976]
  101. Dijksman LM, Hirsch A, Windhausen F, et al. Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation. Int J Cardiol. 2009;131(2):204–11. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18199496]
  102. Dong-Bao L, Qi H, Hong-Wei L, et al. Effects of early angioplasty after fibrinolysis on prognosis of patients with ST-segment elevation acute myocardial infarction. African Journal of Biotechnology. 2011;10(70):15801–15804. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD.
  103. Dragu R, Behar S, Sandach A, et al. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction? Am J Cardiol. 2006;97(8):1142–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16616015]
  104. Drenth DJ, Veeger NJ, Grandjean JG, et al. Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? Eur J Cardiothorac Surg. 2004;25(4):567–71. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15037273]
  105. Drenth DJ, Veeger NJ, Middel B, et al. Comparison of late (four years) functional health status between percutaneous transluminal angioplasty intervention and off-pump left internal mammary artery bypass grafting for isolated high-grade narrowing of the proximal left anterior descending coronary artery. Am J Cardiol. 2004;94(11):1414–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15566914]
  106. Drenth DJ, Veeger NJ, Winter JB, et al. A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. J Am Coll Cardiol. 2002;40(11):1955–60. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12475455]
  107. Drenth DJ, Winter JB, Veeger NJ, et al. Minimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: six months’ angiographic and clinical follow-up of a prospective randomized study. J Thorac Cardiovasc Surg. 2002;124(1):130–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12091818]
  108. Dryja T, Kornacewicz-Jach Z, Goracy J, et al. Treatment of acute ST-segment elevation myocardial infarction in West Pomerania province of Poland. Comparison between primary coronary intervention and thrombolytic therapy. Kardiol Pol. 2006;64(6):591–599. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16810577]
  109. Dzavik V, Beanlands DS, Davies RF, et al. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]--a pilot study). Am J Cardiol. 1994;73(12):856–61. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8184807]
  110. Dzavik V, Buller CE, Lamas GA, et al. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation. 2006;114(23):2449–57. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2785021] [PubMed: 17105848]
  111. Dzavik V, Carere RG, Mancini GB, et al. Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). Am Heart J. 2001;142(2):301–8. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11479470]
  112. Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J. 2003;24(9):828–37. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12727150]
  113. Dzavik V, Sleeper LA, Picard MH, et al. Outcome of patients aged >or=75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J. 2005;149(6):1128–34. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15976798]
  114. Ebbinghaus J, Maier B, Schoeller R, et al. Routine early invasive strategy and in-hospital mortality in women with non-ST-elevation myocardial infarction Results from the Berlin Myocardial Infarction Registry (BMIR). Int J Cardiol. 2011. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 21277642]
  115. Echols MR, Mahaffey KW, Banerjee A, et al. Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). Am J Cardiol. 2007;99(3):315–21. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17261389]
  116. Eefting F, Nathoe H, van Dijk D, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation. 2003;108(23):2870–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14656913]
  117. Eisenberg MJ, Teng FF, Chaudhry MR, et al. Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction: a randomized clinical trial. Am Heart J. 2005;149(5):813–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15894961]
  118. Ekstein S, Elami A, Merin G, et al. Balloon angioplasty versus bypass grafting in the era of coronary stenting. Isr Med Assoc J. 2002;4(8):583–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12183860]
  119. Ellis SG, Mooney MR, George BS, et al. Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Treatment of Post-Thrombolytic Stenoses (TOPS) Study Group. Circulation. 1992;86(5):1400–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 1423952]
  120. Ellis SG, Roubin GS, King SB 3rd, et al. In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures. J Am Coll Cardiol. 1988;11(2):211–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 2963055]
  121. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007;297(18):1985–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17488963]
  122. Farkouh ME, Dangas G, Leon MB, et al. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J. 2008;155(2):215–23. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18215589]
  123. Farkouh ME, Ramanathan K, Aymong ED, et al. An early revascularization strategy is associated with a survival benefit for diabetic patients in cardiogenic shock after acute myocardial infarction. Clin Cardiol. 2006;29(5):204–10. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC6654055] [PubMed: 16739392]
  124. Favarato D, Hueb W, Gersh BJ, et al. Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II Study. Circulation. 2003;108(Suppl 1):II21–3. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12970202]
  125. Favarato ME, Hueb W, Boden WE, et al. Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. Int J Cardiol. 2007;116(3):364–70. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16876891]
  126. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol. 1995;25(2):362–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 7829789]
  127. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364(9439):1045–53. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15380963]
  128. Ferreira-Gonzalez I, Permanyer-Miralda G, Marrugat J, et al. MASCARA (Manejo del Sindrome Coronario Agudo. Registro Actualizado) study. General findings. Rev Esp Cardiol. 2008;61(8):803–16. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 18684363]
  129. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS. J Am Coll Cardiol. 1997;29(7):1505–11. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9180111]
  130. Fosbol EL, Thune JJ, Kelbaek H, et al. Long-term outcome of primary angioplasty compared with fibrinolysis across age groups: a Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) substudy. Am Heart J. 2008;156(2):391–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18657676]
  131. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005;366(9489):914–20. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16154018]
  132. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2863990] [PubMed: 19502645]
  133. Fukunishi M, Nishigaki K, Okubo M, et al. J-SAP study 1–2 outcomes of patients with stable high-risk coronary artery disease receiving medical-preceding therapy in Japan. Circ J. 2006;70(8):1012–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16864934]
  134. Gao RL, Han YL, Yang XC, et al. Thorombolytic therapy with rescue percutaneous coronary intervention versus primary percutaneous coronary intervention in patients with acute myocardial infarction: A multicenter randomized clinical trial. Chin Med J (Engl). 2010;123(11):1365–1372. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20819587]
  135. Garcia E, Elizaga J, Perez-Castellano N, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol. 1999;33(3):605–11. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10080458]
  136. Gaszewska-Zurek E, Zurek P, Ciosek J, et al. Invasive treatment of coronary artery disease in octogenarians. Kardiol Pol. 2005;63(5):488–96. discussion 497–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16362853]
  137. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353(26):2758–68. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16382062]
  138. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med. 1993;328(10):685–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8433727]
  139. Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]). Am J Cardiol. 2011;107(4):501–8. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 21195380]
  140. Goy JJ, Eeckhout E, Burnand B, et al. Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. Lancet. 1994;343(8911):1449–53. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 7911175]
  141. Goy JJ, Eeckhout E, Moret C, et al. Five-year outcome in patients with isolated proximal left anterior descending coronary artery stenosis treated by angioplasty or left internal mammary artery grafting. A prospective trial. Circulation. 1999;99(25):3255–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10385499]
  142. Goy JJ, Kaufmann U, Goy-Eggenberger D, et al. A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. Mayo Clin Proc. 2000;75(11):1116–23. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11075740]
  143. Goy JJ, Kaufmann U, Hurni M, et al. 10-year follow-up of a prospective randomized trial comparing bare-metal stenting with internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis the SIMA (Stenting versus Internal Mammary Artery grafting) trial. J Am Coll Cardiol. 2008;52(10):815–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18755343]
  144. Graham MM, Ghali WA, Faris PD, et al. Survival after coronary revascularization in the elderly. Circulation. 2002;105(20):2378–84. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12021224]
  145. Gray TJ, Burns SM, Clarke SC, et al. Percutaneous myocardial laser revascularization in patients with refractory angina pectoris. Am J Cardiol. 2003;91(6):661–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12633794]
  146. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993;328(10):673–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8433725]
  147. Grines CL, Westerhausen DR Jr, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol. 2002;39(11):1713–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12039480]
  148. Gruberg L, Mercado N, Milo S, et al. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: The obesity paradox II? Am J Cardiol. 2005;95(4):439–44. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15695125]
  149. Gruberg L, Milo S, Ben Tzvi M, et al. Comparison of bypass surgery and stenting for the treatment of multivessel disease: results from the ARTS trial in Israel. Isr Med Assoc J. 2003;5(8):539–42. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12929288]
  150. Gurm HS, Whitlow PL, Kip KE. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol. 2002;39(5):834–40. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11869849]
  151. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109(11):1371–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15007010]
  152. Hartigan PM, Giacomini JC, Folland ED, et al. Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine. Am J Cardiol. 1998;82(12):1445–50. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9874045]
  153. Hassan SA, Hlatky MA, Boothroyd DB, et al. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). Am J Med. 2001;110(4):260–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11239843]
  154. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42(7):1161–70. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14522473]
  155. Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet. 1998;352(9138):1419–25. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9807988]
  156. Henriques JP, Zijlstra F, van ‘t Hof AW, et al. Primary percutaneous coronary intervention versus thrombolytic treatment: long term follow up according to infarct location. Heart. 2006;92(1):75–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1860964] [PubMed: 15831596]
  157. Herz I, Mohr R, Moshkovitz Y, et al. Revascularization of the left anterior descending artery with drug-eluting stents: comparison with arterial off-pump surgery. Heart Surg Forum. 2004;7(5):E490–2. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15799931]
  158. Hirsch A, Windhausen F, Tijssen JG, et al. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet. 2007;369(9564):827–35. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17350451]
  159. Hlatky MA, Bacon C, Boothroyd D, et al. Cognitive function 5 years after randomization to coronary angioplasty or coronary artery bypass graft surgery. Circulation. 1997;96(9 Suppl):II-11–4. discussion II-15. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9386068]
  160. Hlatky MA, Boothroyd D, Horine S, et al. Employment after coronary angioplasty or coronary bypass surgery in patients employed at the time of revascularization. Ann Intern Med. 1998;129(7):543–7. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 9758574]
  161. Hlatky MA, Boothroyd DB, Melsop KA, et al. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation. 2004;110(14):1960–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15451795]
  162. Hlatky MA, Boothroyd DB, Melsop KA, et al. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation. 2009;120(25):2550–8. Exclude - Does not include outcomes of interest. [PMC free article: PMC3403834] [PubMed: 19920002]
  163. Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1997;336(2):92–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8988886]
  164. Hochholzer W, Buettner HJ, Trenk D, et al. Percutaneous coronary intervention versus coronary artery bypass grafting as primary revascularization in patients with acute coronary syndrome. Am J Cardiol. 2008;102(2):173–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18602516]
  165. Hofer S, Doering S, Rumpold G, et al. Determinants of health-related quality of life in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2006;13(3):398–406. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16926670]
  166. Holmes DR Jr, Holubkov R, Vlietstra RE, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol. 1988;12(5):1149–55. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 2971699]
  167. Holmes DR Jr, Kim LJ, Brooks MM, et al. The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation. J Thorac Cardiovasc Surg. 2007;134(1):38–46. 46 e1. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17599484]
  168. Holper EM, Brooks MM, Kim LJ, et al. Effects of heart failure and diabetes mellitus on long-term mortality after coronary revascularization (from the BARI Trial). Am J Cardiol. 2007;100(2):196–202. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17631069]
  169. Hong SJ, Lim DS, Seo HS, et al. Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. Catheter Cardiovasc Interv. 2005;64(1):75–81. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15619278]
  170. Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation. 1998;98(22):2377–82. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9832481]
  171. Hueb WA, Bellotti G, de Oliveira SA, et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol. 1995;26(7):1600–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 7594092]
  172. Hueb WA, Soares PR, Almeida De, Oliveira S, et al. Five-year follow-op of the medicine, angioplasty, or surgery study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. Circulation. 1999;100(19 Suppl):II107–13. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10567287]
  173. Huikeshoven M, van der Sloot JA, Tukkie R, et al. Improved quality of life after XeCl excimer transmyocardial laser revascularization: results of a randomized trial. Lasers Surg Med. 2003;33(1):1–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12866115]
  174. Idorn L, Hofsten DE, Wachtell K, et al. Prevalence and prognostic implications of ST-segment deviations from ambulatory Holter monitoring after ST-segment elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention (a Danish Trial in Acute Myocardial Infarction-2 Substudy). Am J Cardiol. 2007;100(6):937–43. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17826373]
  175. Itoh T, Fukami K, Suzuki T, et al. Comparison of long-term prognostic evaluation between pre-intervention thrombolysis and primary coronary intervention: A prospective randomized trial - Five-year results of the IMPORTANT study. Circ J. 2010;74(8):1625–1634. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20571249]
  176. Janzon M, Levin LA, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J. 2002;23(1):31–40. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11741360]
  177. Janzon M, Levin LA, Swahn E. Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial. Am Heart J. 2004;148(1):114–21. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15215800]
  178. Javaid A, Steinberg DH, Buch AN, et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation. 2007;116(11 Suppl):I200–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17846304]
  179. Jeger RV, Assmann SF, Yehudai L, et al. Causes of death and re-hospitalization in cardiogenic shock. Acute Card Care. 2007;9(1):25–33. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17453536]
  180. Jeger RV, Bonetti PO, Zellweger MJ, et al. Influence of revascularization on long-term outcome in patients > or =75 years of age with diabetes mellitus and angina pectoris. Am J Cardiol. 2005;96(2):193–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16018840]
  181. Jeger RV, Harkness SM, Ramanathan K, et al. Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. Eur Heart J. 2006;27(6):664–70. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16423873]
  182. Jeger RV, Lowe AM, Buller CE, et al. Hemodynamic parameters are prognostically important in cardiogenic shock but similar following early revascularization or initial medical stabilization: a report from the SHOCK Trial. Chest. 2007;132(6):1794–803. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17951622]
  183. Jeger RV, Pfisterer ME. Revascularization in patients 75 years or older with diabetes mellitus and angina pectoris. Cardiol Rev. 2006;23(1):19–23. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD.
  184. Jeger RV, Tseng CH, Hochman JS, et al. Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock--a report from the SHould we revascularize Occluded Coronaries for cardiogenic shocK? (SHOCK) trial and registry. Am Heart J. 2006;152(4):686–92. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16996836]
  185. Johansen A, Hoilund-Carlsen PF, Christensen HW, et al. Use of myocardial perfusion imaging to predict the effectiveness of coronary revascularisation in patients with stable angina pectoris. Eur J Nucl Med Mol Imaging. 2005;32(12):1363–70. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15824925]
  186. Johnston N, Jernberg T, Lagerqvist B, et al. Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease. Am Heart J. 2006;152(6):1052–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17161052]
  187. Kaiser C, Kuster GM, Erne P, et al. Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina--on-treatment analysis of the TIME trial. Eur Heart J. 2004;25(12):1036–42. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15191774]
  188. Kapur A, Bartolini D, Finlay MC, et al. The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease. J Cardiovasc Med (Hagerstown). 2010;11(1):26–33. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19797974]
  189. Kasai T, Kajimoto K, Miyauchi K, et al. Propensity analysis of 12 years outcome after bypass graft or balloon angioplasty in patients with multivessel coronary artery disease. J Cardiol. 2008;52(3):186–194. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19027596]
  190. Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet. 2002;359(9310):920–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11918909]
  191. Kaul P, Armstrong PW, Chang WC, et al. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. Circulation. 2004;110(13):1754–60. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15381645]
  192. Kaul P, Armstrong PW, Fu Y, et al. Impact of different patterns of invasive care on quality of life outcomes in patients with non-ST elevation acute coronary syndrome: results from the GUSTO-IIb Canada-United States substudy. Can J Cardiol. 2004;20(8):760–6. Exclude - Does not include outcomes of interest. [PubMed: 15229756]
  193. Kawecki D, Kubiak G, Orszulik K, et al. Quality of life in patients with severe left ventricle dysfunction due to coronary artery disease. Central European Journal of Medicine. 2011;6(6):807–812. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD.
  194. Kelsey SF, James M, Holubkov AL, et al. Results of percutaneous transluminal coronary angioplasty in women. 1985–1986. National Heart, Lung, and Blood Institute’s Coronary Angioplasty Registry. Circulation. 1993;87(3):720–7. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 8443892]
  195. Kempf J, Buysman E, Brixner D. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting. American Health and Drug Benefits. 2011;4(6):355–361. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC4105734] [PubMed: 25126362]
  196. Kimura T, Morimoto T, Furukawa Y, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. Circulation. 2008;118(14 Suppl):S199–209. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18824755]
  197. King SB 3rd. The Emory Angioplasty vs Surgery Trial (EAST). Semin Interv Cardiol. 1999;4(4):185–90. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10738351]
  198. Kip KE, Alderman EL, Bourassa MG, et al. Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. Circulation. 2002;105(16):1914–20. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11997277]
  199. Kjaergard H, Nielsen PH, Andreasen JJ, et al. Coronary artery bypass grafting within 30 days after treatment of acute myocardial infarctions with angioplasty or fibrinolysis - a surgical substudy of DANAMI-2. Scand Cardiovasc J. 2004;38(3):143–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15223711]
  200. Kjaergard HK, Nielsen PH, Andreasen JJ, et al. Coronary artery bypass grafting within the first year after treatment of large acute myocardial infarctions with angioplasty or fibrinolysis. Scandinavian Cardiovascular Journal. 2006;(1):25–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16448994]
  201. Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2002;40(6):1044–50. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12354426]
  202. Kleopatra K, Muth K, Zahn R, et al. Effect of an invasive strategy on in-hospital outcome and one-year mortality in women with non-ST-elevation myocardial infarction. Int J Cardiol. 2010. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 20851476]
  203. Kofoed KF, Madsen JK, Grande P, et al. Long-term effects of invasive treatment in patients with a post-thrombolytic Q-wave myocardial infarction. Scand Cardiovasc J. 2010;44(3):146–52. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20233135]
  204. Konstance RP, Eisenstein EL, Anstrom KJ, et al. Outcomes of second revascularization procedures after stent implantation. J Med Syst. 2008;32(2):177–86. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18461821]
  205. Kontny F. Improving outcomes in acute coronary syndromes--the FRISC II trial. Clin Cardiol. 2001;24(3 Suppl):13–7. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PMC free article: PMC6655210] [PubMed: 11286312]
  206. Krantz MJ, Haugen SJ, Batal H, et al. Off-site percutaneous coronary intervention reduces hospital length of stay in vulnerable patients with acute myocardial infarction. Crit Pathw Cardiol. 2005;4(3):127–130. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18340197]
  207. Krimly A, Yan RT, Yan AT, et al. Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. Can J Cardiol. 2011;27(6):711–715. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 21875778]
  208. Kruk M, Buller CE, Tcheng JE, et al. Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). Am J Cardiol. 2010;105(1):10–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2825873] [PubMed: 20102883]
  209. Kruk M, Kadziela J, Reynolds HR, et al. Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. JACC Cardiovasc Interv. 2008;1(5):511–20. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2635493] [PubMed: 19194534]
  210. Kuch B, Heier M, von Scheidt W, et al. 20-year trends in clinical characteristics, therapy and short-term prognosis in acute myocardial infarction according to presenting electrocardiogram: the MONICA/KORA AMI Registry 1985–2004. J Intern Med. 2008;264(3):254–64. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18397247]
  211. Kugelmass AD, Sadanandan S, Lakkis N, et al. Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: A report from TACTICS-TIMI 18. Crit Pathw Cardiol. 2006;(3):167–72. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18340233]
  212. Kukreja N, Serruys PW, De Bruyne B, et al. Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II). Heart. 2009;95(13):1061–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19304671]
  213. Kunadian B, Sutton AG, Vijayalakshmi K, et al. Early invasive versus conservative treatment in patients with failed fibrinolysis--no late survival benefit: the final analysis of the Middlesbrough Early Revascularisation to Limit Infarction (MERLIN) randomized trial. Am Heart J. 2007;153(5):763–71. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17452151]
  214. Kurbaan AS, Bowker TJ, Ilsley CD, et al. The effect of adjusting for baseline risk factors and post revascularisation coronary disease on comparisons between coronary angioplasty and bypass surgery. Int J Cardiol. 2001;77(2–3):207–14. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11182184]
  215. Kurbaan AS, Bowker TJ, Ilsley CD, et al. Impact of postangioplasty restenosis on comparisons of outcome between angioplasty and bypass grafting. Coronary Angioplasty versus Bypass Revascularisation Investigation (CABRI) Investigators. Am J Cardiol. 1998;82(3):272–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9708652]
  216. Kurbaan AS, Bowker TJ, Ilsley CD, et al. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol. 2001;87(8):947–50. A3. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11305983]
  217. Kurbaan AS, Bowker TJ, Rickards AF. Trials of angioplasty and surgery: CABRI. Semin Interv Cardiol. 1999;4(4):179–84. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10738350]
  218. Lagerqvist B, Husted S, Kontny F, et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol. 2002;40(11):1902–14. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12475448]
  219. Lam BK, Gillinov AM, Blackstone EH, et al. Importance of moderate ischemic mitral regurgitation. Ann Thorac Surg. 2005;79(2):462–70. discussion 462–70. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15680815]
  220. Lang IM, Forman SA, Maggioni AP, et al. Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). EuroIntervention. 2009;5(5):610–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2893563] [PubMed: 20142183]
  221. Lansky AJ. Outcomes of percutaneous and surgical revascularization in women. Prog Cardiovasc Dis. 2004;46(4):305–19. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 14961454]
  222. Lansky AJ, Goto K, Cristea E, et al. Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Circ Cardiovasc Interv. 2010;(4):308–16. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20647564]
  223. Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol. 2001;37(4):985–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11263625]
  224. Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol. 2005;46(3):417–24. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16053952]
  225. Lee MS, Jamal F, Kedia G, et al. Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. Int J Cardiol. 2007;123(1):34–42. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17292983]
  226. Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2006;47(4):864–70. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16487857]
  227. Legrand VM, Garg S, Serruys PW, et al. Influence of age on the clinical outcomes of coronary revascularisation for the treatment of patients with multivessel de novo coronary artery lesions: sirolimus-eluting stent vs. coronary artery bypass surgery and bare metal stent, insight from the multicentre randomised Arterial Revascularisation Therapy Study Part I (ARTS-I) and Part II (ARTS-II). EuroIntervention. 2011;6(7):838–45. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 21252018]
  228. Legrand VM, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation. 2004;109(9):1114–20. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14993134]
  229. Legutko J, Dudek D, Chyrchel M, et al. [Safety and effectiveness of pharmacologic versus mechanical stabilization of borderline coronary lesions in patients with acute coronary syndromes]. Przegl Lek. 2005;(1):1–7. Exclude - Non-English. [PubMed: 16053211]
  230. Lehmann R, Fichtlscherer S, SchAchinger V, et al. Favorable long-term survival in patients undergoing multivessel-PCI compared to predicted prognosis of CABG estimated by EuroSCORE: Procedural and clinical determinants of long-term outcome. J Interv Cardiol. 2009;22(6):511–519. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 19732282]
  231. Lehmann S, Walther T, Kempfert J, et al. Stentless versus conventional xenograft aortic valve replacement: midterm results of a prospectively randomized trial. Ann Thorac Surg. 2007;84(2):467–72. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17643617]
  232. Lindholm MG, Boesgaard S, Thune JJ, et al. Percutaneous coronary intervention for acute MI does not prevent in-hospital development of cardiogenic shock compared to fibrinolysis. Eur J Heart Fail. 2008;10(7):668–74. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18571985]
  233. Liu YY, Zhou YJ, Wang ZJ, et al. [Comparison between drug eluting stent and coronary artery bypass grafting surgery for the treatment of unprotected left main coronary artery disease in elderly patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37(9):769–72. Exclude - Non-English. [PubMed: 20128370]
  234. Lopes NH, da Paulitsch FS, Gois AF, et al. Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the Medical, Angioplasty, and bypass Surgery study (MASS). Eur J Cardiothorac Surg. 2008;33(3):349–54. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18249128]
  235. Loponen P, Luther M, Korpilahti K, et al. HRQoL after coronary artery bypass grafting and percutaneous coronary intervention for stable angina. Scand Cardiovasc J. 2009;43(2):94–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18819033]
  236. MacK MJ, Banning AP, Serruys PW, et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg. 2011;92(6):2140–2146. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21967819]
  237. Mack MJ, Prince SL, Herbert M, et al. Current clinical outcomes of percutaneous coronary intervention and coronary artery bypass grafting. Ann Thorac Surg. 2008;86(2):496–503. discussion 503. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18640323]
  238. Madsen JK, Nielsen TT, Grande P, et al. Revascularization compared to medical treatment in patients with silent vs. symptomatic residual ischemia after thrombolyzed myocardial infarction--the DANAMI study. Cardiology. 2007;108(4):243–51. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17114878]
  239. Mahmarian JJ, Dakik HA, Filipchuk NG, et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol. 2006;48(12):2458–67. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17174182]
  240. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288(15):1851–8. Exclude - Does not include outcomes of interest. [PubMed: 12377083]
  241. Malek LA, Reynolds HR, Forman SA, et al. Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT). Am Heart J. 2009;157(4):724–32. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2696388] [PubMed: 19332202]
  242. Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. Circulation. 2005;112(9 Suppl):1371–6. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 16159849]
  243. Mancini GBJ, Bates ER, Maron DJ, et al. Quantitative results of baseline angiography and percutaneous coronary intervention in the courage trial. Circ Cardiovasc Qual Outcomes. 2009;2(4):320–327. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20031857]
  244. Mark DB, Pan W, Clapp-Channing NE, et al. Quality of life after late invasive therapy for occluded arteries. N Engl J Med. 2009;360(8):774–83. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2724193] [PubMed: 19228620]
  245. Maron DJ, Spertus JA, Mancini GB, et al. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol. 2009;104(8):1055–62. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19801024]
  246. Martuscelli E, Clementi F, Gallagher MM, et al. Revascularization strategy in patients with multivessel disease and a major vessel chronically occluded; data from the CABRI trial. Eur J Cardiothorac Surg. 2008;33(1):4–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17988889]
  247. Matteau A, Dorais M, Rinfret S, et al. Effectiveness of a change in reperfusion strategy to primary percutaneous coronary intervention in a nonselected population. Can J Cardiol. 2009;25(8):e279–83. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2732382] [PubMed: 19668789]
  248. McCullough PA, Gibson CM, Dibattiste PM, et al. Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. J Interv Cardiol. 2004;17(2):81–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15104769]
  249. McCullough PA, O’Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol. 1998;32(3):596–605. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 9741499]
  250. McCullough PA, O’Neill WW, Graham M, et al. A time-to-treatment analysis in the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Interv Cardiol. 2001;14(4):415–22. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 12053495]
  251. McKhann GM, Grega MA, Borowicz LM Jr, et al. Is there cognitive decline 1 year after CABG? Comparison with surgical and nonsurgical controls. Neurology. 2005;65(7):991–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16107605]
  252. Mehilli J, Kastrati A, Dirschinger J, et al. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA. 2000;284(14):1799–805. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11025832]
  253. Meliga E, Orzan F, Chiribiri A, et al. Surgical revascularization in the ischemic heart disease. Long-term results in a series of consecutive patients selected according to the principles. Minerva Cardioangiol. 2005;53(2):147–52. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15986009]
  254. Menon V, Pearte CA, Buller CE, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J. 2009;30(2):183–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2639108] [PubMed: 19028780]
  255. Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg. 2005;130(2):512–9. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 16077421]
  256. Michalis LK, Stroumbis CS, Pappas K, et al. Treatment of refractory unstable angina in geographically isolated areas without cardiac surgery. Invasive versus conservative strategy (TRUCS study). Eur Heart J. 2000;21(23):1954–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11071801]
  257. Moreira AE, Hueb WA, Soares PR, et al. [Comparative study between the therapeutic effects of surgical myocardial revascularization and coronary angioplasty in equivalent ischemic situations: analysis through myocardial scintigraphy with 99mTc-Sestamibi]. Arq Bras Cardiol. 2005;(2):92–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16113846]
  258. Morice MC, Feldman TE, Mack MJ, et al. Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: Fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS). EuroIntervention. 2011;7(6):670–679. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21959312]
  259. Morrison DA, Sethi G, Sacks J, et al. A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans Affairs. Control Clin Trials. 1999;20(6):601–19. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10588300]
  260. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol. 2001;38(1):143–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11451264]
  261. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol. 2002;40(11):1951–4. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12475454]
  262. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286(19):2405–12. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11712935]
  263. Nathoe HM, Van Dijk D, Jansen EWL, et al. Off-pump coronary artery bypass surgery compared with stent implantation and on-pump bypass surgery: Clinical outcome and cost-effectiveness at one year. Neth Heart J. 2005;13(78):259–268. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2497251] [PubMed: 25696506]
  264. Nicolau JC, Marin-Neto JA, Giraldez RR, et al. A comparison of percutaneous coronary intervention and surgical revascularization after fibrinolysis for acute myocardial infarction. Insights from the InTIME-2 trial. Int J Cardiol. 2007;116(3):383–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17049642]
  265. Nie SP, Ma CS, Lü Q, et al. [Evaluation of early invasive or initially conservative strategies in patients with non-ST-segment elevation acute coronary syndrome at intermediate or high risk]. Zhonghua Xin Xue Guan Bing Za Zhi. 2005;(4):307–11. Exclude - Non-English. [PubMed: 15932657]
  266. Nienaber CA, Rousseau H, Eggebrecht H, et al. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation. 2009;120(25):2519–28. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19996018]
  267. Niles NW, McGrath PD, Malenka D, et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol. 2001;37(4):1008–15. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11263600]
  268. Nishigaki K, Yamazaki T, Kitabatake A, et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv. 2008;1(5):469–79. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19463347]
  269. Nishimi M, Tashiro T. Off-pump coronary artery bypass vs percutaneous coronary intervention. Therapeutic strategies for 3-vessel coronary artery disease: OPCAB vs PCI(PCI-Side). Circ J. 2010;74(12):2750–7. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 21084755]
  270. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43(4):585–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14975468]
  271. Nylaende M, Abdelnoor M, Stranden E, et al. The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication. Eur J Vasc Endovasc Surg. 2007;33(1):3–12. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17055756]
  272. Nylaende M, Kroese AJ, Morken B, et al. Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study. Vasc Med. 2007;12(4):275–83. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18048463]
  273. Ochala A, Smolka GA, Wojakowski W, et al. The function of the left ventricle after complete multivessel one-stage percutaneous coronary intervention in patients with acute myocardial infarction. J Invasive Cardiol. 2004;16(12):699–702. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15596873]
  274. O’Donoghue M, Sabatine MS. Appropriate invasive and conservative treatment approaches for patients with ST-elevation MI. Curr Treat Options Cardiovasc Med. 2006;8(1):3–11. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 16401379]
  275. Ohno T, Kinoshita O, Fujita H, et al. Detecting occult coronary artery disease followed by early coronary artery bypass surgery in patients with diabetic retinopathy: report from a diabetic retinocoronary clinic. J Thorac Cardiovasc Surg. 2010;139(1):92–7. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19660392]
  276. Okumura K, Kamiya H, Matsui H, et al. Beneficial effect of quinapril in patients with angiotensin-converting enzyme D allele after coronary stenting. Atherosclerosis. 2001;159(2):527–8. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 11730835]
  277. Olson KL, Delate T, Rasmussen J, et al. Outcomes of patients discharged from pharmacy-managed cardiovascular disease management. Am J Manag Care. 2009;15(8):497–503. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19670953]
  278. Orth-Gomer K, Schneiderman N, Wang HX, et al. Stress reduction prolongs life in women with coronary disease: the Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes. 2009;2(1):25–32. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20031809]
  279. Ostadal P, Alan D, Vejvoda J, et al. Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome. Exp Clin Cardiol. 2008;13(4):175–178. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC2663480] [PubMed: 19343162]
  280. Ott I, Malcouvier V, Schomig A, et al. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation. 2002;105(3):279–81. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11804978]
  281. Ovbiagele B, Campbell S, Faiz A, et al. Relationship between non-specific prescription pill adherence and ischemic stroke outcomes. Cerebrovasc Dis. 2010;29(2):146–53. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC2813814] [PubMed: 19955739]
  282. Pache J, Kastrati A, Mehilli J, et al. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J. 2004;148(1):e3. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15215812]
  283. Packer M, Coats AJ, Fowler MB. Carvedilol reduced mortality and hospitalisation in severe chronic heart failure. Evidence-Based Medicine. 2001;6(6):173. Exclude - No data for OMT/PCI/CABG comparison of interest.
  284. Paez KA, Allen JK. Cost-effectiveness of nurse practitioner management of hypercholesterolemia following coronary revascularization. J Am Acad Nurse Pract. 2006;18(9):436–44. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16958775]
  285. Pambianco G, Lombardero M, Bittner V, et al. Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Prev Cardiol. 2009;12(1):9–18. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC2717619] [PubMed: 19301686]
  286. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med. 1992;326(1):10–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 1345754]
  287. Parisi AF, Hartigan PM, Folland ED. Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) Study. J Am Coll Cardiol. 1997;30(5):1256–63. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9350924]
  288. Park DW, Yun SC, Lee SW, et al. Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease. Circulation. 2008;117(16):2079–86. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 18413495]
  289. Parodi G, Ndrepepa G, Kastrati A, et al. Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. Am Heart J. 2006;152(6):1133–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17161066]
  290. Parsons E, Newby LK, Bhapkar MV, et al. Postmenopausal hormone use in women with acute coronary syndromes. J Womens Health (Larchmt). 2004;13(8):863–71. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15671702]
  291. Pater C, Jacobsen CD, Rollag A, et al. Design of a randomized controlled trial of comprehensive rehabilitation in patients with myocardial infarction, stabilized acute coronary syndrome, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting: Akershus comprehensive cardiac rehabilitation trial (the CORE study). Curr Control Trials Cardiovasc Med. 2000;1(3):177–183. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC56205] [PubMed: 11714435]
  292. Pedersen S, Galatius S, Bech J, et al. 7,528 patients treated with PCI--a Scandinavian real-life scenario. Cardiology. 2008;110(2):96–105. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17971658]
  293. Pedersen S, Galatius S, Mogelvang R, et al. Long-term prognosis in an ST-segment elevation myocardial infarction population treated with routine primary percutaneous coronary intervention: from clinical trial to real-life experience. Circ Cardiovasc Interv. 2009;2(5):392–400. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20031748]
  294. Pedersen TR, Cater NB, Faergeman O, et al. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiol. 2010;106(3):354–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20643245]
  295. Pell JP, Pell AC, Jeffrey RR, et al. Comparison of survival following coronary artery bypass grafting vs. percutaneous coronary intervention in diabetic and non-diabetic patients: retrospective cohort study of 6320 procedures. Diabet Med. 2004;21(7):790–2. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15209776]
  296. Pereira AC, Lopes NH, Soares PR, et al. Clinical judgment and treatment options in stable multivessel coronary artery disease: results from the one-year follow-up of the MASS II (Medicine, Angioplasty, or Surgery Study II). J Am Coll Cardiol. 2006;48(5):948–53. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16949484]
  297. Pereira AC, Miyakawa AA, Lopes NH, et al. Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization. Thromb Res. 2007;121(1):25–32. Exclude - Does not include outcomes of interest. [PubMed: 17604826]
  298. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108(14):1682–7. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 14504182]
  299. Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation. 2004;110(10):1213–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15337691]
  300. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA. 2003;289(9):1117–23. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12622581]
  301. Pfisterer M, Buser P, Osswald S, et al. Trial of Invasive versus Medical Therapy in the Elderly (TIME): Study protocol and patient outline. HeartDrug. 2001;1(3):144–147. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD.
  302. Picard MH, Davidoff R, Sleeper LA, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation. 2003;107(2):279–84. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12538428]
  303. Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49(21):2105–11. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17531660]
  304. Pilote L, Miller DP, Califf RM, et al. Recurrent ischemia after thrombolysis for acute myocardial infarction. Am Heart J. 2001;141(4):559–65. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11275920]
  305. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006;114(19):2019–25. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17075010]
  306. Pinto DS, Stone GW, Shi C, et al. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008;52(22):1758–68. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19022155]
  307. Pitt B, O’Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87(9):1058–63. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11348602]
  308. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341(2):70–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10395630]
  309. Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation. 1996;94(2):135–42. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8674171]
  310. Pohl T, Giehrl W, Reichart B, et al. Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheter Cardiovasc Interv. 2004;62(3):323–30. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15224298]
  311. Poldermans D, Schouten O, Vidakovic R, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol. 2007;49(17):1763–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17466225]
  312. Poole-Wilson PA, Pocock SJ, Fox KA, et al. Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial. Heart. 2006;92(10):1473–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1861054] [PubMed: 16621882]
  313. Poole-Wilson PA, Voko Z, Kirwan BA, et al. Clinical course of isolated stable angina due to coronary heart disease. Eur Heart J. 2007;28(16):1928–35. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17562665]
  314. Poppe T, Singal B, Cowen M, et al. Is it possible to safely administer early a loading dose of clopidogrel before coronary angiography to patients who are candidates for percutaneous coronary intervention? Am J Cardiol. 2009;104(11):1505–10. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19932783]
  315. Prapas SN, Panagiotopoulos IA, Ayyad MA, et al. Female risk using OPCAB, pi-circuit, and aorta no-touch coronary revascularization. Heart Surg Forum. 2009;12(6):E344–8. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20037100]
  316. Prasad A, Rihal C, Holmes DR Jr. The COURAGE trial in perspective. Catheter Cardiovasc Interv. 2008;72(1):54–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18412271]
  317. Radojkovi DD, Perisi, et al. [Influence of the double antiplatelet therapy on patency of the occluded artery after acute myocardial infarction with ST-segment elevation]. Vojnosanit Pregl. 2007;(2):117–21. Exclude - Non-English. [PubMed: 17348463]
  318. Radovanovic D, Erne P, Schilling J, et al. Association of dyslipidemia and concomitant risk factors with in-hospital mortality in acute coronary syndrome in Switzerland: The acute myocardial infarction and unstable angina registry in Switzerland (AMIS Plus). HeartDrug. 2005;5(3):131–139. Exclude - No data for OMT/PCI/CABG comparison of interest.
  319. Raghunathan A, Rapp JH, Littooy F, et al. Postoperative outcomes for patients undergoing elective revascularization for critical limb ischemia and intermittent claudication: a subanalysis of the Coronary Artery Revascularization Prophylaxis (CARP) trial. J Vasc Surg. 2006;43(6):1175–82. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16765234]
  320. Rajagopal V, Lincoff AM, Cohen DJ, et al. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Am Heart J. 2006;152(1):149–54. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16824845]
  321. Ramanathan KB, Weiman DS, Sacks J, et al. Percutaneous intervention versus coronary bypass surgery for patients older than 70 years of age with high-risk unstable angina. Ann Thorac Surg. 2005;80(4):1340–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16181866]
  322. Rana JS, Mannam A, Donnell-Fink L, et al. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol. 2005;95(12):1456–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15950570]
  323. Rao C, Aziz O, Panesar SS, et al. Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ. 2007;334(7594):621. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PMC free article: PMC1831990] [PubMed: 17337457]
  324. Rao SV, O’Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16253582]
  325. Rashba EJ, Lamas GA, Couderc JP, et al. Electrophysiological effects of late percutaneous coronary intervention for infarct-related coronary artery occlusion: the Occluded Artery Trial-Electrophysiological Mechanisms (OAT-EP). Circulation. 2009;119(6):779–87. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2771659] [PubMed: 19188505]
  326. Rasoul S, Ottervanger JP, Timmer JR, et al. One year outcomes after glucose-insulin-potassium in ST elevation myocardial infarction. The Glucose-insulin-potassium study II. Int J Cardiol. 2007;122(1):52–5. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17223212]
  327. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31(5):561–572. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC2831765] [PubMed: 19942600]
  328. Rastan AJ, Boudriot E, Falk V, et al. Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX study. Eur J Cardiothorac Surg. 2008;34(2):376–82. discussion 382–3. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18579392]
  329. Ratner RE, Cannon CP, Gerstein HC, et al. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. Am Heart J. 2008;156(6):1074–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19033001]
  330. Rauch B, Schiele R, Schneider S, et al. OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction. Circulation. 2010;122(21):2152–2159. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 21060071]
  331. Rauch B, Schiele R, Schneider S, et al. Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study. Cardiovasc Drugs Ther. 2006;20(5):365–75. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17124558]
  332. Ray KK, Nazer B, Cairns R, et al. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. J Thromb Thrombolysis. 2010;30(1):10–3. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20354760]
  333. Reeves BC, Angelini GD, Bryan AJ, et al. A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. Health Technol Assess. 2004;8(16):1–43. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15080865]
  334. Reeves BC, Angelini GD, Bryan AJ, et al. A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. Health Technol Assess. 2004;8(16):iii-38. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15080865]
  335. Reina A, Colmenero M, Aguayo de Hoyos E, et al. Gender differences in management and outcome of patients with acute myocardial infarction. Int J Cardiol. 2007;116(3):389–95. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16843548]
  336. Reynolds HR, Farkouh ME, Lincoff AM, et al. Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med. 2007;167(19):2054–60. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17954798]
  337. Reynolds MR, Neil N, Ho KK, et al. Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience. Am Heart J. 2003;145(2):334–42. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12595853]
  338. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol. 1993;22(2):376–80. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8335807]
  339. Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study. J Am Coll Cardiol. 1998;32(6):1687–94. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9822097]
  340. Riezebos RK, Ronner E, Ter Bals E, et al. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. Heart. 2009;95(10):807–12. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19098058]
  341. Rihal CS, Sutton-Tyrrell K, Guo P, et al. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation. Circulation. 1999;100(2):171–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10402447]
  342. Rinfret S, Kennedy WA, Lachaine J, et al. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen. JACC Cardiovasc Interv. 2010;3(10):1011–1019. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20965458]
  343. Rodes-Cabau J, Bertrand OF, Larose E, et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. Circulation. 2009;120(20):1978–86. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19884468]
  344. Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol. 2001;37(1):51–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11153772]
  345. Rodriguez A, Boullon F, Perez-Balino N, et al. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol. 1993;22(4):1060–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8409041]
  346. Rodriguez A, Mele E, Peyregne E, et al. Three-year follow-up of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease (ERACI). J Am Coll Cardiol. 1996;27(5):1178–84. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8609339]
  347. Rodriguez A, Rodriguez Alemparte M, Baldi J, et al. Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study. Heart. 2003;89(2):184–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1767529] [PubMed: 12527674]
  348. Rodriguez AE, Baldi J, Fernandez Pereira C, et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol. 2005;46(4):582–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16098419]
  349. Roncalli J, Brunelle F, Galinier M, et al. Pre-hospital fibrinolysis followed by angioplasty or primary angioplasty in acute myocardial infarction: the long-term clinical outcome. J Thromb Thrombolysis. 2003;15(3):181–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14739627]
  350. Ronner E, Boersma E, Akkerhuis KM, et al. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J. 2002;23(3):239–46. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11792139]
  351. Rosengart TK, Sweet J, Finnin EB, et al. Neurocognitive functioning in patients undergoing coronary artery bypass graft surgery or percutaneous coronary intervention: evidence of impairment before intervention compared with normal controls. Ann Thorac Surg. 2005;80(4):1327–34. discussion 1334–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16181864]
  352. Rosenson RS, Hislop C, Elliott M, et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010;56(14):1079–1088. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20863951]
  353. Ross AM, Huber K, Zeymer U, et al. The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. JACC Cardiovasc Interv. 2009;2(10):925–30. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19850250]
  354. Rott D, Behar S, Hod H, et al. Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures. Am Heart J. 2001;141(2):267–76. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11174342]
  355. Rouleau J. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am J Med. 2005;118(Suppl 1):2A, 28–35. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16356805]
  356. Rumsfeld JS, Magid DJ, Plomondon ME, et al. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. J Am Coll Cardiol. 2003;41(10):1732–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12767656]
  357. Rupprecht HJ, Hamm C, Ischinger T, et al. Angiographic follow-up results of a randomized study on angioplasty versus bypass surgery (GABI trial). GABI Study Group. Eur Heart J. 1996;17(8):1192–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8869860]
  358. Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin. 2004;20(9):1447–54. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15383193]
  359. Ryan TJ. Present-day PTCR versus CABG: a randomized comparison with a different focus and a new result. J Am Coll Cardiol. 2001;(1):59–62. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 11153773]
  360. Rymuza H, Kowalik I, Drzewiecki A, et al. Successful primary coronary angioplasty improves early and long-term outcomes in ST segment elevation acute coronary syndromes in patients above 80 years of age. Kardiol Pol. 2011;69(4):346–354. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21523668]
  361. Sabatine MS, Blake GJ, Drazner MH, et al. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation. 2005;111(10):1217–24. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15769761]
  362. Sabatine MS, Morrow DA, McCabe CH, et al. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J. 2006;151(1):25–31. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16368287]
  363. Sadanandan S, Cannon CP, Gibson CM, et al. A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44(4):799–803. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15312862]
  364. Salem M, Rotevatn S, Stavnes S, et al. Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris. Am J Cardiol. 2004;93(9):1086–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15110197]
  365. Sanborn TA, Sleeper LA, Webb JG, et al. Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol. 2003;42(8):1373–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14563577]
  366. Sato H, Kinjo K, Ito H, et al. Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study. Circ J. 2008;72(1):17–22. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 18159093]
  367. Saw J, Topol EJ, Steinhubl SR, et al. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. Am J Cardiol. 2004;94(5):623–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15342293]
  368. Sawada SG, Dasgupta S, Nguyen J, et al. Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability. Am J Cardiol. 2010;106(2):187–92. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20599001]
  369. Sawhney N, Moses JW, Leon MB, et al. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation. 2004;110(4):374–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15249503]
  370. Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2003;42(4):634–41. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12932593]
  371. Schettert IT, Pereira AC, Lopes NH, et al. Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease. Thromb Res. 2010;125(1):61–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19427680]
  372. Schettert IT, Pereira AC, Lopes NH, et al. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. Thromb Res. 2006;118(6):679–83. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16405973]
  373. Schinkel AF, Poldermans D, Rizzello V, et al. Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction. J Nucl Med. 2006;47(1):68–73. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16391189]
  374. Schoenenberger AW, Kobza R, Jamshidi P, et al. Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). Am J Cardiol. 2009;104(2):158–63. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19576339]
  375. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med. 2000;343(6):385–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10933737]
  376. Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293(23):2865–72. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15956631]
  377. Schomig A, Ndrepepa G, Mehilli J, et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation. 2003;108(9):1084–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12925458]
  378. Schouten O, van Kuijk JP, Flu WJ, et al. Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study). Am J Cardiol. 2009;103(7):897–901. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19327412]
  379. Schroter S, Lamping DL. Responsiveness of the coronary revascularisation outcome questionnaire compared with the SF-36 and Seattle Angina Questionnaire. Qual Life Res. 2006;15(6):1069–78. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16900287]
  380. Schwartz L, Kip KE, Alderman E, et al. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). Am J Cardiol. 2009;103(5):632–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19231325]
  381. Schweiger MJ, Cannon CP, Murphy SA, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001;88(8):831–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11676942]
  382. Sciahbasi A, Madonna M, De Vita M, et al. Comparison of immediate vs early invasive strategy in patients with first acute non-ST-elevation myocardial infarction. Clin Cardiol. 2010;(10):650–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC6653721] [PubMed: 20960541]
  383. Scott IA, Derhy PH, O’Kane D, et al. Discordance between level of risk and intensity of evidence-based treatment in patients with acute coronary syndromes. Med J Aust. 2007;187(3):153–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17680740]
  384. Sculpher MJ, Seed P, Henderson RA, et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet. 1994;344(8927):927–30. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 7934351]
  385. Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009;104(12):1647–53. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19962469]
  386. Sedlis SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol. 2002;40(9):1555–66. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12427406]
  387. Sedlis SP, Ramanathan KB, Morrison DA, et al. Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). Am J Cardiol. 2004;94(1):118–20. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15219521]
  388. Segev A, Fefer P, Strauss BH, et al. Outcome of patients with acute coronary syndromes enrolled in clinical trials. Coron Artery Dis. 2009;20(7):473–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19609208]
  389. Sejersten M, Birnbaum Y, Ripa RS, et al. Influences of electrocardiographic ischaemia grades and symptom duration on outcomes in patients with acute myocardial infarction treated with thrombolysis versus primary percutaneous coronary intervention: results from the DANAMI-2 trial. Heart. 2006;92(11):1577–82. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1861241] [PubMed: 16740918]
  390. Sejersten M, Ripa RS, Maynard C, et al. Usefulness of quantitative baseline ST-segment elevation for predicting outcomes after primary coronary angioplasty or fibrinolysis (results from the DANAMI-2 trial). Am J Cardiol. 2006;97(5):611–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16490423]
  391. Sejersten M, Valeur N, Grande P, et al. Long-term prognostic value of ST-segment resolution in patients treated with fibrinolysis or primary percutaneous coronary intervention results from the DANAMI-2 (DANish trial in acute myocardial infarction-2). J Am Coll Cardiol. 2009;54(19):1763–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19874989]
  392. Selker HP, Beshansky JR, Griffith JL. Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction. A multicenter, randomized, controlled, clinical effectiveness trial. Ann Intern Med. 2002;137(2):87–95. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 12118963]
  393. Selnes OA, Grega MA, Bailey MM, et al. Cognition 6 years after surgical or medical therapy for coronary artery disease. Ann Neurol. 2008;63(5):581–90. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18481292]
  394. Selnes OA, Grega MA, Borowicz LM Jr, et al. Cognitive changes with coronary artery disease: a prospective study of coronary artery bypass graft patients and nonsurgical controls. Ann Thorac Surg. 2003;75(5):1377–84. discussion 1384–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12735550]
  395. Senior R, Kaul S, Raval U, et al. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol. 2002;9(5):454–62. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 12360125]
  396. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J. 1999;20(1):58–69. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 10075142]
  397. Serruys PW, Klein W, Tijssen JP, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation. 1993;88(4 Pt 1):1588–601. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 8403306]
  398. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19228612]
  399. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46(4):575–81. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16098418]
  400. Serruys PW, Onuma Y, Garg S, et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010;55(11):1093–101. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI or stable CAD. [PubMed: 20171036]
  401. Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation. 1991;84(4):1568–80. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 1833088]
  402. Serruys PW, Unger F, Sousa JE. Stents had similar clinical outcomes but more repeated revascularisation than did bypass surgery in multivessel disease. Evidence-Based Medicine. 2001;6(6):174. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.
  403. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344(15):1117–24. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11297702]
  404. Shah SJ, Waters DD, Barter P, et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008;51(20):1938–43. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 18482661]
  405. Shavelle DM, Salami A, Abdelkarim M, et al. Rescue percutaneous coronary intervention for failed thrombolysis. Catheter Cardiovasc Interv. 2006;67(2):214–20. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16408298]
  406. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18268144]
  407. Shaw LJ, Miller DD, Romeis JC, et al. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med. 1994;120(7):559–66. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 8116993]
  408. Shelton RJ, Crean AM, Somers K, et al. Real-world outcome from ST elevation myocardial infarction in the very elderly before and after the introduction of a 24/7 primary percutaneous coronary intervention service. Am Heart J. 2010;159(6):956–63. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20569706]
  409. Shen W, Zhang R, Shen Y, et al. Optimal timing of coronary stenting in unstable angina patients. Chin Med J (Engl). 2001;114(1):59–61. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11779437]
  410. Shimada K, Mokuno H, Matsunaga E, et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis. 2004;174(2):343–7. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15136065]
  411. Shlipak MG, Browner WS, Noguchi H, et al. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med. 2001;110(6):425–33. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11331052]
  412. Shufelt KA, Paradiso-Hardy FL, Papastergiou J, et al. High mortality with ST elevation myocardial infarction in a nontrial setting. Can J Cardiol. 2004;20(14):1455–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15614341]
  413. Sibbing D, von Beckerath O, von Beckerath N, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. Blood Coagul Fibrinolysis. 2005;16(7):511–5. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16175011]
  414. Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol. 2001;37(1):81–8. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11153777]
  415. Silva JC, Rochitte CE, Junior JS, et al. Late coronary artery recanalization effects on left ventricular remodelling and contractility by magnetic resonance imaging. Eur Heart J. 2005;26(1):36–43. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15615797]
  416. Silva PR, Hueb WA, César LA, et al. [Comparative study of the results of coronary artery bypass grafting and angioplasty for myocardial revascularization in patients with equivalent multivessel disease]. Arq Bras Cardiol. 2005;84(3):214–21. Exclude - Non-English. [PubMed: 15867994]
  417. Simes RJ, O’Connell RL, Aylward PE, et al. Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Am Heart J. 2010;159(6):988–97. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20569711]
  418. Singh M, Gersh BJ, McClelland RL, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation. 2004;109(22):2727–31. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15173022]
  419. Singh M, Gersh BJ, McClelland RL, et al. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol. 2005;45(2):198–203. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15653015]
  420. Singh M, White J, Hasdai D, et al. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol. 2007;50(18):1752–8. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17964038]
  421. Singh M, Williams BA, Gersh BJ, et al. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. J Am Coll Cardiol. 2006;47(1):34–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16386661]
  422. Singh SM, Alter DA. Is routine early invasive management of non-ST-segment elevation myocardial infarction beneficial in elderly patients? CMAJ. 2004;171(9):1046–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC526326] [PubMed: 15546173]
  423. Sinkovic A, Marinsek M, Svensek F. Women and men with unstable angina and/or non-ST-elevation myocardial infarction. Wien Klin Wochenschr. 2006;118(Suppl 2):52–7. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16817045]
  424. Sinkovic A, Pehnec Z. In-hospital mortality and treatment in elderly patients with ST-elevation myocardial infarction. Journal fur Kardiologie. 2005;12(11 12):282–284. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD.
  425. Sinnaeve PR, Ezekowitz JA, Bogaerts K, et al. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. Eur Heart J. 2009;30(18):2213–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19586960]
  426. Sleeper LA, Reynolds HR, White HD, et al. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry. Am Heart J. 2010;160(3):443–50. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC4229030] [PubMed: 20826251]
  427. Soares PR, Hueb WA, Lemos PA, et al. Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II). Circulation. 2006;114(1 Suppl):I420–4. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16820611]
  428. Sobolev BG, Levy AR, Kuramoto L, et al. The risk of death associated with delayed coronary artery bypass surgery. BMC Health Serv Res. 2006;6(85) Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1574305] [PubMed: 16822309]
  429. Solodky A, Assali AR, Behar S, et al. Anterior wall myocardial infarction in real world: does reperfusion strategy make any differences? Catheter Cardiovasc Interv. 2004;61(1):79–83. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14696164]
  430. Solomon DH, Stone PH, Glynn RJ, et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol. 2001;38(4):969–76. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11583866]
  431. Sorajja P, Gersh BJ, Cox DA, et al. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2010;55(14):1416–24. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20359590]
  432. Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study Eur Heart J. 2002;23(3):230–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11792138]
  433. Spertus JA, Jones PG, Coen M, et al. Transmyocardial CO(2) laser revascularization improves symptoms, function, and quality of life: 12-month results from a randomized controlled trial. Am J Med. 2001;111(5):341–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11583635]
  434. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation. 2003;108(23):2851–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14623806]
  435. Steg PG, Francois L, Iung B, et al. Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction. Eur Heart J. 2005;26(18):1831–7. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15930039]
  436. Steg PG, Kerner A, Mancini GB, et al. Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. Circulation. 2010;121(25):2724–30. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2900832] [PubMed: 20547926]
  437. Steg PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J. 2004;25(24):2187–94. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15589635]
  438. Steigen TK, Buller CE, Mancini GB, et al. Myocardial perfusion grade after late infarct artery recanalization is associated with global and regional left ventricular function at one year: analysis from the Total Occlusion Study of Canada-2. Circ Cardiovasc Interv. 2010;3(6):549–55. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC3640427] [PubMed: 21062997]
  439. Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J. 2007;154(1):3–11. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 17584547]
  440. Stone GW, Teirstein PS, Rubenstein R, et al. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. J Am Coll Cardiol. 2002;39(10):1581–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12020483]
  441. Stroupe KT, Morrison DA, Hlatky MA, et al. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation. 2006;114(12):1251–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16966588]
  442. Sutton AG, Campbell PG, Graham R, et al. One year results of the Middlesbrough early revascularisation to limit infarction (MERLIN) trial. Heart. 2005;91(10):1330–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1769146] [PubMed: 16162629]
  443. Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol. 2004;44(2):287–96. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15261920]
  444. Svensson L, Aasa M, Dellborg M, et al. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. Am Heart J. 2006;151(4):798 e1–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16569536]
  445. Swahn E. Invasive strategy among women with Non-ST-Elevation Acute Coronary Syndrome. ACC Cardiosource Review Journal. 2007;16(10):29–30. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.
  446. Szalma I, Kiss A, Kardos L, et al. Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo. Ann Thorac Surg. 2006;82(4):1430–5. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16996947]
  447. Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation. 2002;105(19):2253–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12010906]
  448. Szygula-Jurkiewicz B, Zembala M, Wilczek K, et al. Health related quality of life after percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with acute coronary syndromes without ST-segment elevation. 12-Month follow up. Eur J Cardiothorac Surg. 2005;(5):882–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15848330]
  449. Tackett AH, Bailey AL, Foody JM, et al. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial. Am Heart J. 2010;160(4):678–684. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20934562]
  450. Takiuti ME, Hueb W, Hiscock SB, et al. Quality of life after surgical myocardial revascularization, angioplasty or medical treatment. Arq Bras Cardiol. 2007;88(5):537–44. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17589628]
  451. Tamis-Holland J, Lu J, Korytkowski M, et al. Lack of Sex-Based Differences in Outcomes in Patients with Type 2 Diabetes and Coronary Artery Disease Treated with Contemporary Medical Therapy with or without Prompt Revascularization: A Report from BARI 2D. 59th Annual Scientific Session of the American College of Cardiology (ACC 2010). 2010. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 23500245]
  452. ten Berg JM, Kelder JC, Suttorp MJ, et al. Influence of planned six-month follow-up angiography on late outcome after percutaneous coronary intervention: a randomized study. J Am Coll Cardiol. 2001;38(4):1061–9. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11583883]
  453. Teo KK, Sedlis SP, Boden WE, et al. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. J Am Coll Cardiol. 2009;54(14):1303–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19778673]
  454. Teo KK, Sedlis SP, Boden WE, et al. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention in Older Patients With Stable Coronary Disease. A Pre-Specified Subset Analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) Trial. J Am Coll Cardiol. 2009;54(14):1303–1308. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19778673]
  455. Testa L, Van Gaal WJ, Bhindi R, et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg. 2008;136(4):884–93. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 18954626]
  456. Thiele H, Engelmann L, Elsner K, et al. Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 2005;26(19):1956–63. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16061501]
  457. Thiele H, Kappl MJ, Linke A, et al. Influence of time-to-treatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging. Eur Heart J. 2007;28(12):1433–9. Exclude - Does not include outcomes of interest. [PubMed: 17556347]
  458. Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol. 2009;53(25):2324–31. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19539141]
  459. Thiele H, Oettel S, Jacobs S, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. Circulation. 2005;112(22):3445–50. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16316966]
  460. Thiele H, Scholz M, Engelmann L, et al. ST-segment recovery and prognosis in patients with ST-elevation myocardial infarction reperfused by prehospital combination fibrinolysis, prehospital initiated facilitated percutaneous coronary intervention, or primary percutaneous coronary intervention. Am J Cardiol. 2006;98(9):1132–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17056313]
  461. Thomas SB, Sansing VV, Davis A, et al. Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial. Am J Public Health. 2010;100(Suppl 1):S269–76. Exclude - No data for OMT/PCI/CABG comparison of interest. [PMC free article: PMC2837445] [PubMed: 20147671]
  462. Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation. 2005;112(13):2017–21. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16186438]
  463. Timmer JR, Ottervanger JP, de Boer MJ, et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med. 2007;167(13):1353–9. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 17620527]
  464. Timmer JR, Ottervanger JP, Thomas K, et al. Long-term, cause-specific mortality after myocardial infarction in diabetes. Eur Heart J. 2004;25(11):926–31. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15172464]
  465. Tio RA, Tan ES, Jessurun GA, et al. PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. J Nucl Med. 2004;45(9):1437–43. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15347709]
  466. Tjandrawidjaja MC, Fu Y, Goodman SG, et al. The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. Eur Heart J. 2003;24(11):1024–34. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 12788302]
  467. Tornvall P, Johansson M, Herzfeld I, et al. [A controlled trial with prolonged follow up: percutaneous intervention in acute myocardial infarction is equivalent to thrombolytic therapy]. Läkartidningen. 2001;(32–33):3397–9. Exclude - Non-English. [PubMed: 11526657]
  468. Tricoci P, Lokhnygina Y, Berdan LG, et al. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007;116(23):2669–77. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 18025532]
  469. Trzos E, Kurpesa M, Forys J, et al. [Outcomes of primary coronary angioplasty, thrombolysis and pharmacological therapy for the management of acute myocardial infarction in elderly patients]. Polski Przeglad Kardiologiczny. 2005;(3):219–26. Exclude - Non-English.
  470. Türel B, Gemici K, Baran I, et al. Effects of glucose-insulin-potassium solution added to reperfusion treatment in acute myocardial infarction. Anadolu Kardiyol Derg. 2005;(2):90–4. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15939681]
  471. Tygesen H, Wettervik C, Wennerblom B. Intensive home-based exercise training in cardiac rehabilitation increases exercise capacity and heart rate variability. Int J Cardiol. 2001;79(2–3):175–82. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11461739]
  472. Udelson JE, Pearte CA, Kimmelstiel CD, et al. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. Am Heart J. 2011;161(3):611–21. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC3073850] [PubMed: 21392619]
  473. Unger F, Serruys PW, Yacoub MH, et al. Revascularization in multivessel disease: comparison between two-year outcomes of coronary bypass surgery and stenting. J Thorac Cardiovasc Surg. 2003;125(4):809–20. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12698143]
  474. Uriel N, Moravsky G, Blatt A, et al. Acute myocardial infarction with spontaneous reperfusion: clinical characteristics and optimal timing for revascularization. Isr Med Assoc J. 2007;9(4):243–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17491214]
  475. Valeur N, Clemmensen P, Grande P, et al. Pre-discharge exercise test for evaluation of patients with complete or incomplete revascularization following primary percutaneous coronary intervention: a DANAMI-2 sub-study. Cardiology. 2008;109(3):163–71. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17726317]
  476. Valeur N, Clemmensen P, Saunamaki K, et al. The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study. Eur Heart J. 2005;26(2):119–27. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15618067]
  477. van der Sloot JA, Huikeshoven M, Tukkie R, et al. Transmyocardial revascularization using an XeCl excimer laser: results of a randomized trial. Ann Thorac Surg. 2004;78(3):875–81. discussion 881–2. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15337012]
  478. van Dijk D, Nierich AP, Eefting FD, et al. The Octopus Study: rationale and design of two randomized trials on medical effectiveness, safety, and cost-effectiveness of bypass surgery on the beating heart. Control Clin Trials. 2000;21(6):595–609. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 11146152]
  479. van Domburg RT, Sonnenschein K, Nieuwlaat R, et al. Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction. J Am Coll Cardiol. 2005;46(1):15–20. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15992629]
  480. van Domburg RT, Takkenberg JJ, Noordzij LJ, et al. Late outcome after stenting or coronary artery bypass surgery for the treatment of multivessel disease: a single-center matched-propensity controlled cohort study. Ann Thorac Surg. 2005;79(5):1563–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15854934]
  481. van Gaal WJ, Arnold JR, Testa L, et al. Myocardial injury following coronary artery surgery versus angioplasty (MICASA): a randomised trial using biochemical markers and cardiac magnetic resonance imaging. EuroIntervention. 2011;6(6):703–10. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21205592]
  482. van Rees Vellinga TE, Peters RJ, Yusuf S, et al. Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. Am Heart J. 2010;160(6):1049–55. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 21146657]
  483. van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes. 2006;4(20) Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1475841] [PubMed: 16563170]
  484. van ‘t Hof AW, de Vries ST, Dambrink JH, et al. A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes. Eur Heart J. 2003;24(15):1401–5. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 12909068]
  485. Vanasse A, Courteau J, Niyonsenga T. Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients’ survival when delivered as usual care. BMC Cardiovasc Disord. 2006;6(21) Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1473199] [PubMed: 16674817]
  486. Venskutonyte L, Malmberg K, Norhammar A, et al. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes. J Intern Med. 2010;268(1):75–82. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 20210844]
  487. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart. 1999;82(4):426–31. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC1760265] [PubMed: 10490554]
  488. Vrachatis AD, Alpert MA, Georgulas VP, et al. Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count. Angiology. 2001;52(3):161–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11269778]
  489. Wahrborg P. Quality of life after coronary angioplasty or bypass surgery. 1-year follow-up in the Coronary Angioplasty versus Bypass Revascularization investigation (CABRI) trial. Eur Heart J. 1999;20(9):653–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10208785]
  490. Wahrborg P, Booth JE, Clayton T, et al. Neuropsychological outcome after percutaneous coronary intervention or coronary artery bypass grafting: results from the Stent or Surgery (SoS) Trial. Circulation. 2004;110(22):3411–7. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 15557380]
  491. Ward HB, Kelly RF, Thottapurathu L, et al. Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. Ann Thorac Surg. 2006;82(3):795–800. discussion 800–1. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16928485]
  492. Waters D. Comparison of aggressive lipid lowering with Atorvastatin vs. Revascularization Treatments (AVERT) and conventional care for the reduction of ischemic events in patients with stable coronary artery disease. Cardiovasc Rev Rep. 2000;21(1):26–31. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD.
  493. Watkins S, Thiemann D, Coresh J, et al. Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities. Am J Cardiol. 2005;96(10):1349–55. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16275176]
  494. Webb JG, Lowe AM, Sanborn TA, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol. 2003;42(8):1380–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 14563578]
  495. Webb JG, Sanborn TA, Sleeper LA, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J. 2001;141(6):964–70. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11376311]
  496. Weintraub WS, Becker ER, Mauldin PD, et al. Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST). Am J Cardiol. 2000;86(7):747–52. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11018194]
  497. Weintraub WS, Boden WE, Zhang Z, et al. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1(1):12–20. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 20031783]
  498. Weintraub WS, Mahoney EM, Zhang Z, et al. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart. 2004;90(7):782–8. Exclude - Does not include outcomes of interest. [PMC free article: PMC1768324] [PubMed: 15201249]
  499. Weintraub WS, Mauldin PD, Becker E, et al. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation. 1995;92(10):2831–40. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 7586249]
  500. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677–87. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 18703470]
  501. Weintraub WS, Wenger NK, Kosinski AS, et al. Percutaneous transluminal coronary angioplasty in women compared with men. J Am Coll Cardiol. 1994;24(1):81–90. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 8006286]
  502. Westerhout CM, Bonnefoy E, Welsh RC, et al. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J. 2011;161(2):283–90. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 21315210]
  503. Wexler LF, Blaustein AS, Lavori PW, et al. Non-Q-wave myocardial infarction following thrombolytic therapy: a comparison of outcomes in patients randomized to invasive or conservative post-infarct assessment strategies in the Veterans Affairs non-Q-wave Infarction Strategies In-Hospital (VANQWISH) Trial. J Am Coll Cardiol. 2001;37(1):19–25. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11153737]
  504. Wharton TP Jr, Grines LL, Turco MA, et al. Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site (the PAMI-No SOS study) versus transfer to surgical centers for primary angioplasty. J Am Coll Cardiol. 2004;43(11):1943–50. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15172395]
  505. White AJ, Kedia G, Mirocha JM, et al. Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. JACC Cardiovasc Interv. 2008;1(3):236–45. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19463306]
  506. White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation. 2005;112(13):1992–2001. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16186436]
  507. Widimsky P, Bilkova D, Penicka M, et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years’ follow-up of the PRAGUE-2 Trial. Eur Heart J. 2007;28(6):679–84. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17298968]
  508. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J. 2003;24(1):94–104. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12559941]
  509. Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J. 2000;21(10):823–31. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10781354]
  510. Widimsky P, Motovska Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J. 2008;29(12):1495–503. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PMC free article: PMC2429977] [PubMed: 18441320]
  511. Wijeysundera HC, You JJ, Nallamothu BK, et al. An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: a meta-analysis of contemporary randomized controlled trials. Am Heart J. 2008;156(3):564–572. 572 e1–2. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 18760142]
  512. Winchester DE, Wen X, Xie L, et al. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol. 2010;56(14):1099–109. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 20825761]
  513. Windhausen F, Hirsch A, Tijssen JG, et al. ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in non-ST-elevation acute coronary syndromes A substudy of the Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) Trial. J Electrocardiol. 2007;40(5):408–15. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17604045]
  514. Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116(14):1540–8. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17848615]
  515. Wong A, Mak KH, Chan C, et al. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study. Catheter Cardiovasc Interv. 2004;62(4):445–52. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 15274152]
  516. Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation. 2002;106(2):202–7. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 12105159]
  517. Wong JA, Goodman SG, Yan RT, et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. Eur Heart J. 2009;30(5):549–57. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 19201761]
  518. Wong SC, Sleeper LA, Monrad ES, et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. J Am Coll Cardiol. 2001;38(5):1395–401. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 11691514]
  519. Yamagata K, Kataoka Y, Kokubu N, et al. A 3-year clinical outcome after percutaneous coronary intervention using sirolimus-eluting stent and off-pump coronary artery bypass grafting for the treatment of diabetic patients with multivessel disease. Circ J. 2010;74(4):671–8. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 20154406]
  520. Yan AT, Yan RT, Cantor WJ, et al. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: Insights from the Trial of Routine ANgioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Eur Heart J. 2011;32(16):1994–2002. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21307037]
  521. Yan AT, Yan RT, Tan M, et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med. 2007;167(10):1009–16. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17533203]
  522. Yan AT, Yan RT, Tan M, et al. Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. Am Heart J. 2007;153(4):500–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17383285]
  523. Yan Q, Changsheng M, Shaoping N, et al. Percutaneous treatment with drug-eluting stent vs bypass surgery in patients suffering from chronic stable angina with multivessel disease involving significant proximal stenosis in left anterior descending artery. Circ J. 2009;73(10):1848–55. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 19713656]
  524. Yang SS, Li WM, Yin LL, et al. [Chronic effects of percutaneous transmyocardial laser revascularization in patients with refractory angina]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;(1):51–4. Exclude - Non-English. [PubMed: 17386166]
  525. Yang X, Alexander KP, Chen AY, et al. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46(8):1490–5. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16226173]
  526. Yang YM, Zhu J, Tan HQ, et al. [Clinical characteristics and management of patients with ST segment elevation myocardial infarction in China: survey of 7510 cases]. Zhonghua Yi Xue Za Zhi. 2005;(31):2176–82. Exclude - Non-English. [PubMed: 16321179]
  527. Yin L, Li GP, Liu T, et al. Role of probucol in preventing contrast induced acute kidney injury after coronary interventional procedure: a randomized trial. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;(5):385–8. Exclude - Non-English. [PubMed: 19781209]
  528. Yip HK, Wu CJ, Chang HW, et al. Comparison of primary angioplasty and conservative treatment on short- and long-term outcome in octogenarian or older patients with acute myocardial infarction. Jpn Heart J. 2002;43(5):463–74. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 12452304]
  529. Yousef ZR, Redwood SR, Bucknall CA, et al. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol. 2002;40(5):869–76. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12225709]
  530. Yuval R, Halon DA, Lewis BS. Perceived disability and lifestyle modification following hospitalization for non-ST elevation versus ST elevation acute coronary syndromes: the patients’ point of view. Eur J Cardiovasc Nurs. 2007;6(4):287–92. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 17449324]
  531. Zachorski M, Dziuk M, Pietrzykowski J, et al. [Left ventricular function in gated single photon emission computed tomography (GSPET) in patients with myocardial infarction subjected to thrombolysis or primary PTCA]. Pol Merkur Lekarski. 2005;(106):376–9. Exclude - Non-English. [PubMed: 16161914]
  532. Zeymer U, Gitt A, Junger C, et al. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction. Thromb Haemost. 2008;99(1):150–4. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 18217147]
  533. Zeymer U, Gitt A, Junger C, et al. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice. Am J Cardiol. 2006;98(1):19–22. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 16784913]
  534. Zeymer U, Schroder R, Machnig T, et al. Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction. Am Heart J. 2003;146(4):686–91. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 14564324]
  535. Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001;38(6):1644–50. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 11704395]
  536. Zeymer U, Uebis R, Vogt A, et al. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte. Circulation. 2003;108(11):1324–8. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12939210]
  537. Zhang Q, Zhang RY, Zhang JS, et al. Outcomes of primary percutaneous coronary intervention for acute ST-elevation myocardial infarction in patients aged over 75 years. Chin Med J (Engl). 2006;119(14):1151–6. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16863605]
  538. Zhang Z, Kolm P, Boden WE, et al. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina. Circ Cardiovasc Qual Outcomes. 2011;4(2):172–82. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 21304091]
  539. Zhang Z, Mahoney EM, Spertus JA, et al. The impact of age on outcomes after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: one-year results from the Stent or Surgery (SoS) trial. Am Heart J. 2006;152(6):1153–60. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 17161069]
  540. Zhang Z, Spertus JA, Mahoney EM, et al. The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial. Am Heart J. 2005;150(1):175–81. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 16084166]
  541. Zhao XQ, Kosinski AS, Barnhart HX, et al. Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. Med Sci Monit. 2003;9(2):CR48–54. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 12601286]
  542. Ziegelstein RC, Hilbe JM, French WJ, et al. Magnesium use in the treatment of acute myocardial infarction in the United States (observations from the Second National Registry of Myocardial Infarction). Am J Cardiol. 2001;87(1):7–10. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 11137825]
  543. Zijlstra F, Beukema WP, van ‘t Hof AW, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol. 1997;29(5):908–12. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 9120174]
  544. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328(10):680–4. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 8433726]
  545. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341(19):1413–9. Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/STEMI, NSTEMI, or stable CAD. [PubMed: 10547403]
  546. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate 2–4h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002;23(7):550–7. Exclude - Study type is not RCT, prospective or retrospective observational study, or registry. [PubMed: 11922645]
  547. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2002;90(5):533–6. Exclude - No data for OMT/PCI/CABG comparison of interest. [PubMed: 12208418]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.7M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...